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The supply of COVID-19 vaccine doses still lags behind the global demand for first time vaccination and booster
doses. Distribution of vaccine doses has been far from equitable across the world given the steep prices and
logistical challenges that low- and middle-income countries face. Subunit protein vaccine candidates have now
been shown to elicit protective responses against SARS-CoV-2 infection, while providing additional benefits for
manufacturing capability and stability requirements compared to many currently approved vaccines. Here we
report a second-generation engineered RBD sequence variant with enhanced manufacturability and
immunogenicity over the wild-type ancestral RBD and a first-generation engineered variant (RBD-L452K-F490W
(RBD-J)). Introducing two additional mutations, S383D and L518D, to a hydrophobic cryptic epitope in the RBD
core improved expression titers and biophysical stability compared to RBD-J. These two additional mutations in
RBD-S383D-L452K-F490W-L518D (RBD-J6) ablated the interaction of two neutralizing antibodies, CR3022 and
EY6A, targeting the class 4 epitope on the RBD core, but the protein is still bound by human convalescent sera.
Mice immunized with a Beta sequence variant of RBD-J and RBD-J6 displayed on a virus-like particle were
protected against challenges with Alpha and Beta variants of SARS-CoV-2. Sera from mice immunized with
three doses of a RBD-J6 β – VLP showed comparable neutralizing activity to several variants of concern
compared to two doses of Comirnaty.

Figure 1. Mutations to hydrophobic surface on RBD core improved secreted titers of RBD.
(a) Computational analysis of RBD reveals hydrophobic patches on surface (red). Mutations to RBD core
reduced surface hydrophobicity. (b) Pairwise combinations of mutations to RBD-core improve secretion titers of
RBD measured by reverse phase liquid chromatography.
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